At a glance
- Originator Pfizer
- Developer Schering-Plough
- Class
- Mechanism of Action Neurokinin 1 antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cough
- Discontinued Allergic rhinitis; Arrhythmias; Asthma; Nausea and vomiting; Pain; Rheumatic disorders
Most Recent Events
- 04 Aug 2009 No development reported - Preclinical for Cough in USA (IV)
- 21 Jun 2004 Data presented at the 100th International Conference of the American Thoracic Society (ATS-2004) have been added to the Respiratory Tract Disorders pharmacodynamics section
- 06 Apr 2004 Preclinical trials in Cough in USA (unspecified route)